At the end of the original 72-week study, people on the highest dose of either medication were randomized into two arms: the treatment group taking a once-daily dose of orforglipron and a placebo control group
Comparing Ozempic, Wegovy and Other GLP-1 Drugs GoodRx [Internet]
108 LC15-0444 (a DPP4inh) decreased inflammatory and fibrotic indicators like TGF1, toll-like receptor 4, HMGB1, NADPH oxidase 4, nuclear factor kappa B, and modified Smad2/3 in this TGF-driven model
Following up on an executive order last month requiring the feds to make sure AI tools dont result in inequity in health care organizations, todays rule mandates MA plans cover services equitably and does not discriminate, no matter if a decision spawns from an AI system or not
The TRANSCEND-T2D-1 phase 3 trial expanded the evaluation of this pharmacotherapy, a medical treatment using pharmaceutical drugs, to patients with type 2 diabetes [2]